COMMUNIQUÉS West-GlobeNewswire

-
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
01/06/2024 -
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
01/06/2024 -
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
01/06/2024 -
Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT®▼ (amivantamab) for the treatment of patients with EGFR-mutated non-small cell lung cancer
31/05/2024 -
RYBREVANT®▼ (amivantamab) plus lazertinib shows longer progression-free survival versus osimertinib in the first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer
31/05/2024 -
Mainz Biomed Reports Results of 2024 Annual General Meeting
31/05/2024 -
Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor’s Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution
31/05/2024 -
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
31/05/2024 -
Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to July 3, 2024
31/05/2024 -
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
31/05/2024 -
Fortrea lance une solution complète pour améliorer la diversité et l’inclusion dans la recherche clinique
31/05/2024 -
EAACI Congress Kicks Off in Valencia, Spain
31/05/2024 -
Smart for Life to be Featured in Whole Foods Magazine Highlighting Product Offerings, Strategic Acquisitions and Expansion Initiatives
31/05/2024 -
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
31/05/2024 -
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
31/05/2024 -
Valneva reçoit un avis positif du CHMP pour une autorisation de mise sur le marché en Europe de son vaccin contre le chikungunya
31/05/2024 -
OPKO Health to Participate in the Jefferies Global Healthcare Conference
31/05/2024 -
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
31/05/2024 -
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
31/05/2024
Pages